EGFR and cancer: For example, gefitinib effectively eliminates EGFR-mutated lung adenocarcinomas at the beginning of therapy, but the cancers recur in 90% of patients within 2 years.64 Recurrence of lung cancer occurs mainly due to persistent early lesions that are resistant to the anti-cancer drug.